Gene Therapy in Patients With Mucopolysaccharidosis Disease

Mucopolysaccharidosis Type VI Clinical Trial

Official title:

A Phase I/II Open Label, Dose Escalation, Safety Study in Subjects With Mucopolysaccharidosis Type VI (MPS VI) Using Adeno-Associated Viral Vector 8 to Deliver the Human ARSB Gene to Liver

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03173521
• Other study ID #: TIGEM1-MPS VI
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: July 17, 2017
• Est. completion date: September 30, 2025

Study information

• Verified date: November 2021
• Source: Fondazione Telethon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study investigated the safety and efficacy of gene therapy approaches for Mucopolysaccharidosis type VI disease caused by the deficiency of arylsulfatase B (ARSB) enzyme. The aim of the study is to evaluate the safety and efficacy of the treatment.

Description:

Mucopolysaccharidosis type VI disease is involved in Lysosomal Storage Disorder. The MPS VI disease is characterized by growth retardation, corneal clouding, cardiac valve disease, organomegaly, skeletal dysplasia, without central nervous system involvement.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 9
• Est. completion date: September 30, 2025
• Est. primary completion date: June 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Documented biochemical and molecular diagnosis of MPS VI. Testing for homozygous or compound heterozygous disease-causing mutations of the ARSB gene must have been performed by an accredited laboratory.

2. Subjects must be of 4 years of age or older.

3. Subjects should have received ERT for at least 12 months before enrolment and should continue to receive ERT until 7-14 days before IMP administration.

4. Documented informed consent; willingness to adhere to protocol and to participate to long-term follow-up, as evidenced by written informed consent.

Exclusion Criteria:

1. Subjects unable or unwilling to meet requirements of the study.

2. Participation in a clinical study with an investigational drug in the 6 months prior to enrolment in this trial.

3. Subjects unable to perform the 6MWT.

4. History of severe anaphylactoid reaction to Naglazyme in subjects receiving ERT that could affect the safety (severe reaction is meant to be a respiratory impairment event that is life-threatening).

5. Presence of tracheostomy or need of ventilatory assistance.

6. Subjects with evidence of progressive myelomalacia that is considered severe enough to require neck surgery in the first six months after enrolment.

7. Values of AST or ALT above the upper limit of normal range at baseline 2 (at -5days) evaluations.

8. Co-existence of chronic diseases or clinically relevant abnormal baseline laboratory values; infections with hepatitis B, C, or HIV (Baseline 1).

9. Systemic corticosteroid therapy or other immunosuppressive/immunomodulating drugs within 2 months prior to IMP administration.

10. Female individuals of childbearing age who are pregnant or nursing or unwilling to use effective contraception for at least one year post-IMP administration.

11. Fertile male individuals who are unwilling to use male barrier contraceptives such as condom.

12. Any other condition that would not allow the subject to complete follow-up examinations during the course of the study and that, in the opinion of the Investigator, would make the subject unsuitable for the study.

13. Presence of serum NAB to AAV8 above the limit of detection of the assay (Screening and Baseline 1).

14. Presence of serum antibodies anti-ARSB above the upper limit of detection of the assay (antibodies anti-ARSB level >31250 or declared positive at the value of serum dilution 1.10 according to the performed assay) at Screening and Baseline 1.

Related Conditions & MeSH terms

• Mucopolysaccharidoses
• Mucopolysaccharidosis Type VI
• Mucopolysaccharidosis VI

Intervention

Biological:
• AAV2/8.TBG.hARSB
Adeno-associated viral vector serotype 8 with liver-specific thyroxinebinding globulin (TBG) promoter driving the expression of the human ARSB gene. Four dose levels are available: Starting dose is 6x1011 gc of vector per kg of body weight; High dose is 2x1012 gc of vector per kg of body weight and will be administered after at least two subjects at the starting dose have experienced no DLT; Very high dose is 6x1012 vector per kg of body weight and will be administered after three subjects at the high dose have experienced no DLT; Low dose is 2x1011 gc of vector per kg of body weight. Intermediate doses are also possible. The administration of the IMP will be performed into a peripheral vein. The IMP final volume to be injected is calculated based on the patient's weight (determined on the day of hospital admission), as 3 mL/kg.

Locations

Country	Name	City	State
Italy	Department of Translational Medicine (DISMET) of "Federico II" University, Naples	Naples
Turkey	Children's Hospital Hacettepe University	Ankara

Sponsors (1)

Lead Sponsor	Collaborator
Fondazione Telethon

Countries where clinical trial is conducted

Italy,  Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability of the IMP administration	Overall safety and tolerability will be determined through monitoring of adverse events, laboratory and clinical investigations and imaging studies (for example complete physical examination with vital signs recording, liver ultrasound, measurement of transaminases, thyroids hormones, creatinine, albumin, total proteins in blood and urine, and urea, C3 and C4 in blood).	From GT up to 5 years post IMP administration at the following visits: days 1,2,3; weeks 2,3,6,7,8,9,10,11,12,13,14; months 4,9,12; years 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5.
Primary	Primary efficacy outcome - Urinary GAG levels	To determine the efficacy of gene therapy, post-injection urinary GAG excretion levels will be compared to the average of pre-injection urinary GAG determined at baseline 1 and at visit 1.	From GT up to 5 years post IMP administration at the following visits: days 1,2,3; months 4,9,12,15; years 1.5,1.75, 2, 2.5, 3, 4, 5.
Secondary	Secondary efficacy outcome - endurance	Endurance as measured by 6-minute walk test (6MWT) in walking subjects, 3-minute stair climb test (3MSCT) in walking subjects.	From GT up to 5 years post IMP administration at the following visits: months 4,9,12; years 1.5, 2, 2.5, 3.
Secondary	Secondary efficacy outcome - lung volumes	Forced vital capacity (FVC), and forced expiratory volume at 1 second (FEV1) in cooperative subjects.	From GT up to 5 years post IMP administration at the following visits: months 4,9,12; years 1.5, 2, 2.5, 3.